This invention in the pancreas of the non invasive object, being the method of deciding the cell population, the process which prescribes the vesicular mono amine trance porter 2 type (VMAT2) - unique radioactive ligand of the effective quantity to the aforementioned object Concerning at least the portion of the pancreas of the aforementioned object, the process which at least acquires the computer conversion picture of 1 And, in the pancreas of the aforementioned object, in order that the cell population is decided, including the process which it measures analyzes the aforementioned computer conversion picture, it offers the method of becoming. In addition, as for this invention, the method of diagnosing nervous incretion obstacle such as insurinoma, diabetes, and the front clinical diabetes in the metabolism object, and the method of deciding the disposal efficiency of metabolism obstacle are offered. Furthermore, this invention diabetes offers the method of managing the disposal or prevention of method, and the diabetes which appraise the convalescence of the object which has the fear of emerging. In addition, this invention in the pancreas of the object, the kit which is used for the diagnosis of metabolism obstacle or nervous incretion obstacle of decision, and the object of the cell population is offered.< Selective figure >It is not本発明は、非侵襲的な対象の膵臓におけるβ細胞集団を決定する方法であって、有効量の小胞モノアミントランスポーター2型(VMAT2)-特異的放射性リガンドを前記対象に投与する工程;前記対象の膵臓の少なくとも一部について、少なくとも1のコンピュータ化画像を取得する工程;及び、前記対象の膵臓におけるβ細胞集団を決定するべく、前記コンピュータ化画像を定量分析する工程を含んでなる方法を提供する。また、本発明は、代謝対象におけるインスリノーマ、糖尿病、及び前臨床糖尿病等の神経内分泌障害を診断する方法、並びに、代謝障害の処置効率を決定する方法を提供する。更に、本発明は、糖尿病を発症するおそれのある対象の予後を評価する方法、及び、糖尿病の処置又は予防を管理する方法を提供する。また、本発明は、対象の膵臓におけるβ細胞集団の決定、及び、対象の代謝障害又は神経内分泌障害の診断に使用されるキットを提供する。【選択図】なし
